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Impaired osteogenesis of T1DM bone
marrow-derived stromal cells and
periosteum-derived cells and their
differential in-vitro responses to growth
factor rescue
Tera M. Filion1, Jordan D. Skelly1, Henry Huang1, Dale L. Greiner2, David C. Ayers1 and Jie Song1*
Abstract
Background: Poor bone quality, increased fracture risks, and impaired bone healing are orthopedic comorbidities
of type 1 diabetes (T1DM). Standard osteogenic growth factor treatments are inadequate in fully rescuing retarded
healing of traumatic T1DM long bone injuries where both periosteal and bone marrow niches are disrupted. We
test the hypotheses that osteogenesis of bone marrow-derived stromal cells (BMSCs) and periosteum-derived cells
(PDCs), two critical skeletal progenitors in long bone healing, are both impaired in T1DM and that they respond
differentially to osteogenic bone morphogenetic proteins (BMPs) and/or insulin-like growth factor-1 (IGF-1) rescue.
Methods: BMSCs and PDCs were isolated from Biobreeding Diabetes Prone/Worcester rats acquiring T1DM and
normal Wistar rats. Proliferation, osteogenesis, and adipogenesis of the diabetic progenitors were compared with
normal controls. Responses of diabetic progenitors to osteogenesis rescue by rhBMP-2/7 heterodimer (45 or
300 ng/ml) and/or rhIGF-1 (15 or 100 ng/ml) in normal and high glucose cultures were examined by alizarin red
staining and qPCR.
Results: Diabetic BMSCs and PDCs proliferated slower and underwent poorer osteogenesis than nondiabetic
controls, and these impairments were exacerbated in high glucose cultures. Osteogenesis of diabetic PDCs was
rescued by rhBMP-2/7 or rhBMP-2/7 + rhIGF-1 in both normal and high glucose cultures in a dose-dependent
manner. Diabetic BMSCs, however, only responded to 300 ng/nl rhBMP-2/7 with/without 100 ng/ml rhIGF-1 in
normal but not high glucose osteogenic culture. IGF-1 alone was insufficient in rescuing the osteogenesis of either
diabetic progenitor. Supplementing rhBMP-2/7 in high glucose osteogenic culture significantly enhanced gene
expressions of type 1 collagen (Col 1), osteocalcin (OCN), and glucose transporter 1 (GLUT1) while suppressing that
of adipogenic marker peroxisome proliferator-activated receptor gamma (PPARγ) in diabetic PDCs. The same
treatment in high glucose culture only resulted in a moderate increase in Col 1, but no significant changes in OCN
or GLUT1 expressions in diabetic BMSCs.
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Conclusions: This study demonstrates more effective osteogenesis rescue of diabetic PDCs than BMSCs by
rhBMP-2/7 with/without rhIGF-1 in a hyperglycemia environment, underscoring the necessity to tailor biochemical
therapeutics to specific skeletal progenitor niches. Our data also suggest potential benefits of combining growth
factor treatment with blood glucose management to optimize orthopedic therapeutic outcomes for T1DM patients.
Keywords: Type 1 diabetes, Bone marrow-derived stromal cell, Periosteum-derived cell, Osteogenesis,
Hyperglycemia, Growth factor rescue, Bone morphogenetic protein-2/7 heterodimer, Insulin-like growth factor-1
Background
Type 1 diabetes (T1DM) is an inflammatory autoimmune
disease characterized by the destruction of pancreatic beta
cells resulting in insulin deficiency, hyperglycemia, and
subsequent systemic health-related problems for those
affected [1]. Approximately 1.25 million Americans are
living with T1DM, which contributes to the $176 billion
healthcare costs associated with diabetes in the USA in
2012 [2]. T1DM patients are at increased risks for bone
fracture throughout life [3] due to compromised biomech-
anical integrity (increased brittleness) of bone [4], likely
due to advanced glycation end product-mediated collagen
crosslinking and inhibition of osteoblastic function [5, 6],
and higher tendency for developing osteoporosis [7].
Meanwhile, bone healing in patients with poorly con-
trolled T1DM is significantly compromised [8, 9], and
growth hormone dysfunction, growth factor deficiencies,
poor vascularization, neuropathy, and systemic and local
inflammation have all been identified as potential contrib-
utors [8–10]. Increased adipogenicity in bone marrow
[11], impaired osteoblastic activity/osteogenesis of bone
marrow cells [12] and endochondral ossification [13], and
high blood glucose-induced cellular senescence and
apoptosis [14] have also been implicated in the bone
pathology in T1DM.
Stem cells residing within different bone niche envi-
ronments play distinct roles in bone healing, with bone
marrow-derived stromal cells (BMSCs) contributing to
intramembranous ossification and periosteum-derived
cells (PDCs) contributing to endochondral ossification
[15–17]. In traumatic long bone injuries, both the
marrow cavity and periosteum are disrupted. The extent
of injury to the bone and surrounding tissues could
significantly compromise their effective healing [18].
Such a challenge is even more pronounced in the
presence of DM. How skeletal progenitor BMSCs and
PDCs are differentially impaired in T1DM, however, has
not been carefully examined. This limitation has pre-
vented effective therapeutic strategies for expediting
T1DM bone healing from being developed, particularly
the exceptionally challenging regenerative repair of
critical size long bone injuries in diabetic patients.
T1DM rodents with impaired bone healing are
valuable models for elucidating underlying cellular and
molecular mechanisms of the orthopedic comorbidity of
T1DM and developing potential bone healing therapies
[19]. The widely used streptozotocin-induced T1DM
rodents show decreased proliferation and osteogenic
differentiation potential of BMSCs [12, 20, 21]. The
systemic toxicity of streptozotocin [19], however, makes
it difficult to carry out long-term evaluation of retarded
bone healing in the chemically treated rodents because
they tend to become very sick. Biobreeding Diabetes
Prone/Worcester (BBDP) rats that spontaneously ac-
quire the T1DM phenotype [22] more closely mimic
clinically observed T1DM in that they spontaneously
develop pancreatic insulitis similar to humans with
T1DM, followed by selective beta cell destruction and
diabetes [23]. They have been shown to exhibit compro-
mised bone healing [24] and decreased osteoblastic
activity [21], and thus are attractive alternatives. Sys-
temic [25] and local [26] insulin deliveries were shown
to rescue fracture healing in diabetic BBDP rats, but the
restored blood glucose did not reflect the clinical scenar-
ios faced by T1DM patients with poorly controlled
glycemia. High doses of osteogenic growth factor bone
morphogenetic protein-2 (3.6 μg rhBMP-2) were shown
to promote the repair of noncritical size (3 mm) femoral
defects in diabetic BBDP rats with poor glycemic control
[27], but such a BMP-2 dose, when scaled up to the
human, could present significant safety issues. Consist-
ent with literature, we found that an osteoconductive
synthetic bone graft in combination with 400 ng osteo-
genic rhBMP-2/7 heterodimer that functionally heals
(with restoration of torsional strength) 5-mm critical
femoral segmental defects in normal rats [28] was
unable to bridge the same defects in diabetic BBDP rats
with poorly controlled glycemia. Overall, safe and
effective therapeutic strategies promoting the functional
healing of critical long bone defects in T1DM BBDP
rats with poorly controlled glycemia are still lacking,
and the cellular mechanism underscoring such a challenge
is yet to be fully elucidated.
Here we test the hypothesis that in-vitro osteogenesis
of BMSCs and PDCs isolated from T1DM BBDP rats is
impaired and that diabetic BMSCs and PDCs differen-
tially respond to the rescue by potent osteogenic factor
rhBMP-2/7 heterodimer and/or insulin growth factor
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rhIGF-1 in normal and high glucose cultures. Previous
studies reported lower serum IGF-1 along with higher
inflammatory cytokines and lower bone mineral density
in T1DM patients with poor glycemic control than those
with good glycemic control [29–31]. We first confirmed
that the proliferation and osteogenesis of these diabetic
BMSCs and PDCs were differentially impaired and these
impairments were exacerbated in high glucose cultures.
We then demonstrated that the osteogenesis of diabetic
PDCs could be fully rescued by the supplementation of
osteogenic growth factor rhBMP-2/7 heterodimer in
both normal glucose and high glucose cultures in a
dose-dependent manner. rhIGF-1 alone, however, could
not sufficiently rescue the osteogenesis of diabetic PDCs
in either normal or high glucose culture. The dual treat-
ment of rhBMP-2/7 and rhIGF-1 resulted in most robust
osteogenesis rescue of diabetic PDCs, although no
apparent synergistic benefit beyond the sum of enhance-
ments of the respective single factor treatments was
observed. By contrast, we showed that the highly
impaired osteogenesis of diabetic BMSCs could only be
rescued by rhBMP-2/7 or rhBMP-2/7 + rhIGF-1 in
normal glucose culture, but not in high glucose cultures.
qPCR analyses corroborated drastically different
responses by diabetic BMSCs and PDCs to rhBMP-2/7
treatment in cultures simulating the hyperglycemia
microenvironment, suggesting the benefit of simultan-
eous glycemic control and growth factor therapy. This
study underscores the need for tailoring therapeutic
strategies to specific skeletal progenitor niches for
improved therapeutic outcomes.
Methods
Maintenance of T1DM BBDP rats
All animal procedures were carried out per protocol
A-1783 approved by the University of Massachusetts
Medical School Institutional Animal Care and Use
Committee. Four 4-week-old male BBDP rats (Biomed-
ical Research Models, Inc., Worcester, MA, USA) were
monitored for blood glucose (4-h fasting prior to meas-
urement) and weight changes twice a week for the onset
of T1DM. After two consecutive blood glucose readings
of >250 mg/dl (onset as early as 9 weeks), the rats were
considered to have acquired the T1DM phenotype. One
rat was sacrificed upon confirmation of DM for isolation
of freshly diabetic BMSCs and PDCs to investigate cell
proliferation in high vs normal glucose cultures, while
the others were given insulin implants (LinShin Canada,
Inc.), delivered by a trocar to the back neck, to prevent
excessive weight loss while maintaining blood glucose
between 250 and 500 mg/dl emulating T1DM with poor
glycemic control. The rats with more extended DM were
maintained until ~100 days old before they were
sacrificed for BMSC and PDC isolation for differenti-
ation experiments.
Isolation of diabetic and normal BMSCs and PDCs
BMSCs and PDCs were isolated as described previously
[32] from long bones of either freshly diabetic BBDP
rats, those with more extended T1DM (blood glucose
maintained at 250–500 mg/dl, ~100 days), or healthy
nondiabetic male Wistar rats (~100 days old; Charles
River Lab). Wistar rats were chosen as normal non-
diabetic controls because the BBDP rats were derived
from the Wistar strain [23]. Although a small percentage
of BBDP rats fail to develop the TIDM phenotype by
90 days, these rats are not appropriate as normal
controls because they may simply have a later DM onset.
Meanwhile, Biobreeding Diabetes Resistant/Worcester
(BBDR) rats that are resistant to DM development have
also been shown to exhibit abnormal cellular phenotypes
[33], and thus are also unsuited as normal controls.
Briefly, marrow was flushed from femurs and tibias
and pelleted before the red blood cells were lysed with
sterile water. After centrifugation, the cell pellet was
resuspended in expansion media (α-MEM without as-
corbic acid with 20% FBS, 1% penicillin–streptomycin,
and 1% l-glutamine), passed through a sterile swinney
filter, and seeded (10 million/100-mm plate) for adherent
culture. Media were changed on day 4 and three times a
week thereafter. PDCs were isolated from femoral and
tibial periosteum by enzymatic digestion. Briefly, the
muscle was dissected to expose periosteal tissue, which
was carefully scraped from the bone surface and digested in
2.5-mg/ml collagenase, type 2 (Worthington, Lakewood,
NJ, USA) in α-MEM without ascorbic acid for 2 h under
agitation at 37 °C. Cells were pelleted, resuspended in
expansion media, and plated on 100-mm plates (two plates
per leg). Medium was changed on day 4 and three times a
week thereafter.
Given the general difficulty in expanding diabetic cells
into higher passages, we used cells from no later than
passage 2 for all experiments. To ensure consistency in
the growth factor rescue experiments across all treat-
ment conditions (with/without growth factors in six
single/combination doses, normal and high glucose
cultures; see Figs. 2 and 4), passage 2 diabetic cells from
the same BBDP rat with extended T1DM that most
readily expanded to passage 2 were used.
Cell proliferation and β-galactosidase staining
BMSCs and PDCs were plated in six-well tissue culture
plates (n = 3) with an initial seeding density of 20,000
cells/well, and cultured in high glucose (25 mM) or nor-
mal glucose (5.5 mM) expansion media for cell counting
up to 7 days, using a separate plate for each time point.
In a parallel set of experiments (n = 2), cells were fixed
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and stained on days 1, 4, and 6 for β-galactosidase
activity as an indicator of senescence per the literature
protocol [34].
Osteogenic and adipogenic differentiation and growth
factor rescue
BMSCs and PDCs were first cultured in high or normal
glucose expansion media (n = 3) until 70–90%
confluency before being switched to either osteogenic
media (high or normal glucose expansion media supple-
mented with 10 nM dexamethasone, 20 mM β-glycerol
phosphate, and 50 μM 1-ascorbic acid 2-phosphate) or
adipogenic media (expansion media supplemented with
0.5 μM dexamethasone, 0.5 μM isobutylmethylxanthine,
and 50 μM indomethacin). It should be noted that dia-
betic BMSCs were preconditioned in high glucose ex-
pansion media for a longer period than diabetic PDCs
due to the extremely slow proliferation of the former
(requiring a longer time for diabetic BMSCs to reach the
desired confluency for differentiation induction). After
14 days of culture in the respective differentiation media,
cells were fixed for alizarin red or oil red staining. In a
parallel set of experiments, rhBMP-2/7 (45 or 300 ng),
rhIGF-1 (15 or 100 ng), or a combination of both
growth factors (45 ng rhBMP-2/7 + 15 ng rhIGF-1, or
300 ng rhBMP-2/7 + 100 ng rhIGF-1) were supple-
mented to the osteogenic media to assess their abilities
to rescue impaired osteogenic differentiation of the dia-
betic cells in normal and high glucose cultures (n = 4).
Staining was also carried out on cells cultured in both
high and normal glucose expansion media (negative con-
trol). After photo-documentation of the alizarin red and
oil red staining, the dye was released for quantitation
per the literature protocol [32, 35].
qPCR
Following 14 days of culture in high glucose osteogenic
media with or without 300 ng rhBMP-2/7, total RNA
was isolated from diabetic BMSCs and PDCs using
TRIzol (Invitrogen, Carlsbad, CA, USA) and purified by
Direct-Zol miniprep (Zymo Research, Irvine, CA, USA)
following the vendor’s instructions. RNA was reverse
transcribed into cDNA with SuperScript III Reverse
Transcriptase (Invitrogen) according to the vendor’s
instructions on a GeneAmp 2700 PCR system (Applied
Biosystems, Foster City, CA, USA). qPCR (n = 3) was
carried out on an Applied Biosystems 7500 Fast Real-
Time PCR system with TaqMan Gene Expression Master
Mix (Applied Biosystems) and inventoried TaqMan
probes for bone gamma-carboxyglutamate protein
(BGLAP), also known as osteocalcin (OCN), type 1
collagen (COL1), glucose transporter 1 (GLUT1), per-
oxisome proliferator-activated receptor gamma (PPARγ),
and housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). Gene expression was quanti-
fied using the delta–delta Ct method. Relative expression
of each gene in a given cell type in the high glucose cul-
ture with rhBMP2/7 treatment is compared with the
respective cultures without BMP-2/7 rescue (set as 1).
Statistical analysis
Student’s t test was applied for pairwise comparisons be-
tween diabetic and normal cells for a given culture
induction (Fig. 1), between high and normal glucose cul-
tures for a given diabetic progenitor at a given time
point (Fig. 3), and between high glucose cultures with
and without 300 ng/ml rhBMP-2/7 for a given diabetic
cell type (Fig. 5). One-way analysis of variance (ANOVA)
with Tukey post-hoc testing was applied for pairwise
comparisons in single/combination growth factor rescue
experiments (Figs 2 and 4). p < 0.05 was considered
significant and all error bars represent the standard devi-
ation of the mean.
Results
Proliferation and osteogenic differentiation of diabetic
BMSCs and PDCs is impaired in normal glucose cultures
BMSCs and PDCs were isolated from the long bones of
skeletally mature BBDP rats with established T1DM or
normal (nondiabetic) Wistar rats for in-vitro character-
izations. Both diabetic BMSCs and PDCs proliferated
much slower than their nondiabetic controls in normal
glucose (5.5 mM) culture (Fig. 1a) whereas PDCs prolif-
erated more rapidly than their BMSC counterparts in
general. Beta-gal staining revealed a larger senescent cell
population (blue stain) in diabetic BMSC and PDC cul-
tures as compared with their nondiabetic counterparts
(Fig. 1b). Diabetic BMSCs and PDCs also exhibited
impaired osteogenesis compared with their nondiabetic
counterparts, as shown by significantly reduced alizarin
red staining for mineral deposition after 2-week osteo-
genic induction (Fig. 1c, d). Although the osteogenesis
of diabetic PDCs was severely suppressed, no significant
difference in induced adipogenesis between diabetic and
nondiabetic PDCs was observed by oil red staining
(Fig. 1e, f ). By contrast, diabetic BMSCs underwent far
more potent adipogenesis than normal BMSCs upon
culture induction (Fig. 1e, f ).
Impaired osteogenic differentiation of diabetic PDCs and
BMSCs can be rescued by rhBMP-2/7 and rhBMP-2/7 +
rhIGF-1 treatments in normal glucose culture
As IGF-1, an anabolic factor for skeletal growth [36],
is reduced in T1DM patients with poor glycemic
control [29–31], we examined whether supplementing
osteogenic cultures of diabetic BMSCs and PDCs with
potent osteogenic factor rhBMP-2/7 heterodimer [28]
and/or rhIGF-1 may rescue their osteogenesis. In normal
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glucose (5.5 mM) osteogenic culture, rhBMP2/7 supple-
ment enhanced the osteogenesis of diabetic BMSCs and
PDCs in a dose-dependent manner, as indicated by
alizarin red staining (Fig. 2a, b), to a level comparable to
(for diabetic BMSCs with 45 ng/ml rhBMP-2/7) or beyond
those of normal progenitors in response to osteogenic
inductions in the absence of BMP-2/7 (normal controls in
Fig. 1c, d). Although 100 ng/ml rhIGF-1 treatment alone
also appeared to have a positive effect on the osteogenesis
of diabetic progenitors, it did not result in statistically
significant increase in alizarin red staining by 2 weeks,
failing to rescue the impaired osteogenesis to the level of
their normal progenitors. The combination of 100 ng/ml
rhIGF-1 and 300 ng/ml rhBMP-2/7 was the most
potent, resulting in over 6-fold and 26-fold increases
in alizarin red staining after 2 weeks of osteogenic
induction of diabetic BMSCs and diabetic PDCs,
respectively (Fig. 2b). Such enhanced levels of alizarin
red staining were also 2.5 and 5.7 times those ob-
served with normal BMSCs and PDCs upon 2-week
osteogenic induction in the absence of rhBMP-2/7
(Fig. 1d), respectively. However, we did not observe
synergistic benefit of the dual growth factor treatment
beyond the sum of the enhancements from respective
single growth factor treatments.
High glucose further impairs proliferation of diabetic
BMSCs and inhibits the growth factor rescue of
osteogenesis of diabetic BMSCs
Literature in-vitro studies examining BMSC dysfunctions
induced by hyperglycemia typically utilize glucose
concentrations ranging from 12 to 30 mM [37–39]. Here
we show that the proliferation of diabetic BMSCs was
further inhibited in high (25 mM) glucose cultures
Fig. 1 Impaired proliferation and osteogenic differentiation of diabetic BBDP BMSCs and PDCs in normal glucose (5.5 mM) cultures. a Cell
proliferation (n = 3). b β-Galactosidase staining (blue) for senescent cells. Magnification: 50×; c, d Alizarin red staining and quantification (n = 3)
after 14-day normal glucose osteogenic culture. Scale bars = 100 μm; e, f Oil red staining and quantification (n = 3) after 14-day adipogenic culture.
Scale bars = 100 μm. *p < 0.05 (Student’s t test) for pairwise comparisons between cultures for a given cell type; error bars, standard deviation of
the mean. All differences in cell numbers (a) between cultures at a given time point were significant (p < 0.05). BBDP Biobreeding Diabetes Prone/
Worcester, BMSC bone marrow-derived stromal cell, PDC periosteum-derived cell
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compared with normal glucose cultures (Fig. 3). The
adopted 25 mM glucose concentration, nearly a 4.5-fold
increase over the normal glucose (5.5 mM) culture,
approximates the upper end of fold increases in blood
glucose permitted in the T1DM BBDP rat maintenance
designed to emulate poorly controlled glycemia. The
proliferation of diabetic PDCs also slowed in high
glucose culture (Fig. 3), but the difference was not
statistically significant.
Compared with normal glucose osteogenic culture,
high glucose osteogenic cultures appeared to further
inhibit the osteogenesis of diabetic BMSCs, and such
suppression could not be rescued by the supplementa-
tion of rhBMP-2/7 (45 or 300 ng/ml), rhIGF-1 (15 or
100 ng/ml), or their combination (Fig. 4a left, b top). By
contrast, diabetic PDCs were able to respond to rhBMP-
2/7 (45 or 300 ng/ml) treatment in a dose-dependent
manner, resulting in statistically significant increases in
alizarin red staining (Fig. 4a right, b bottom), exceeding
that of normal PDCs upon osteogenic induction in
normal glucose culture without rhBMP-2/7 (normal
PDCs in Fig. 1d). The combination treatment, both
15 ng IGF-1 + 45 ng BMP-2/7 and 100 ng IGF-1 +
300 ng BMP-2/7, resulted in statistically significant
further enhancement in alizarin red staining of diabetic
PDCs in the high glucose culture, with the latter achiev-
ing >12-fold increase over that of the no-growth factor
control, or >2-fold increase over that observed with
normal PDCs in normal glucose osteogenic media
without growth factors (Fig. 1d).
To further elucidate how diabetic progenitors differen-
tially respond to the more potent BMP-2/7 treatment in
high glucose osteogenic culture, gene expressions by
diabetic PDCs and BMSCs were analyzed by qPCR after
2-week high glucose osteogenic inductions with/without
300 ng/ml rhBMP-2/7. Specifically, the expression of
early stage osteogenesis marker COL1, osteoblast-
secreted late stage marker OCN critical for matrix
mineralization [40], GLUT1 responsible for glucose up-
take (its expression found to positively correlates with
Fig. 2 In-vitro rescue of impaired osteogenic differentiation of diabetic
BMSCs and PDCs in normal glucose culture. a Optical micrographs
(100×) and b quantification (n=4) of alizarin red staining for osteogenesis
of diabetic BMSCs and PDCs rescued by rhBMP-2/7 (45 or 300 ng/ml),
rhIGF-1 (15 or 100 ng/ml), or their combinations after 2 weeks in normal
glucose (5.5 mM) osteogenic media. *p< 0.05 (ANOVA) for pairwise
comparisons with those cultured in osteogenic media without growth
factor treatment (* directly above the data bars) or between single and
dual growth factor treatments (* above the brackets indicating specific
data pairs compared); error bars, standard deviation of the mean. O.M.
osteogenic media, BMP-2/7 bone morphogenetic protein-2/7 heterodimer,
BMSC bone marrow-derived stromal cell, IGF-1 insulin-like growth factor-1,
PDC periosteum-derived cell
Fig. 3 High glucose culture further impairs the proliferation of diabetic
BMSCs and PDCs. Cells isolated from diabetic BBDP rats (n = 3) were
cultured in normal (5.5 mM) or high (25 mM) glucose expansion media
and were counted every other day for 1 week. *p < 0.05 (Student’s t
test) for pairwise comparisons between high and normal glucose
cultures for a given cell type at a given time point. Error bars, standard
deviation of the mean. BMSC bone marrow-derived stromal cell, PDC
periosteum-derived cell
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osteogenesis [41]), and adipogenesis marker PPARγ re-
sponsible for fatty acid storage and glucose metabolism
was quantified. Diabetic PDCs showed significantly
higher (by approximately 17-fold, Fig. 5a) expression of
osteogenesis marker COL1, which precedes matrix
mineralization, in response to rhBMP-2/7 treatment in
high glucose osteogenic culture, while diabetic BMSCs
only responded to the growth factor supplement by a 3-
fold increase in COL1 gene expression (Fig. 5b). The less
effective rescue of COL1 expression in diabetic BMSC
was accompanied by the complete failure in rescuing the
gene expression of later-stage osteogenesis marker OCN
(Fig. 5b), consistent with the lack of mineralized matrix
staining by alizarin red (Fig. 4a, left). By contrast,
rhBMP-2/7 treatment resulted in a statistically signifi-
cant increase (~1.8-fold) in OCN gene expression in
diabetic PDCs in the high glucose culture (Fig. 5a),
agreeing with the successful rescue of the secretion of
mineralized matrix shown by alizarin red staining
(Fig. 4a, right). Meanwhile, GLUT1 expression was also
enhanced in diabetic PDCs (~1.8-fold, Fig. 5a) with
rhBMP-2/7 treatment but not in diabetic BMSCs
(Fig. 5b). Finally, whereas the successful BMP-2/7 rescue
of the osteogenesis of diabetic PDCs resulted in an ex-
pected decrease (2.2-fold, Fig. 5a) in the gene expression
of adipogenesis marker PPARγ, the failed rescue in dia-
betic BMSCs was accompanied by a statistically signifi-
cant increase (~1.4-fold) in PPARγ expression (Fig. 5b).
Discussion
Although T1DM is known for orthopedic comorbidities
such as decreased bone mineral density/volume, in-
creased fracture risk, and impaired bone healing, effect-
ive therapeutic strategies for rescuing delayed T1DM
bone healing are lacking. Whether and how different
skeletal progenitor cells involved in long bone healing
are differentially impaired in T1DM, thereby impacting
their relative responsiveness to standard growth factor
therapies, have not been carefully examined. In this
study, a noticeable fraction of BMSCs and PDCs isolated
from BBDP rats with newly acquired T1DM phenotype
were found senescent. The diabetic BMSCs and PDCs
exhibited significantly impaired in-vitro proliferation
and underwent much poorer osteogenic differenti-
ation, as revealed by alizarin red staining of
Fig. 4 High glucose inhibits growth factor rescue of impaired
osteogenic differentiation of diabetic BMSCs but not the rescue of
osteogenesis of diabetic PDCs. a Optical micrographs (100 × x) and
b quantification (n = 4) of alizarin red stain for osteogenesis of diabetic
BMSCs and PDCs after 2-week culture in high glucose (25 mM)
osteogenic media supplemented with rhBMP-2/7 (45 or 300 ng/ml),
rhIGF-1 (15 or 100 ng/ml), or their combination. *p < 0.05 (ANOVA) for
pairwise comparisons with that cultured in osteogenic media without
growth factor treatment (* directly above the data bars) or between
single and dual growth factor treatments (* above the brackets indicating
specific data pairs compared); error bars, standard deviation of the mean.
O.M. osteogenic media, BMP-2/7 bone morphogenetic protein-2/7
heterodimer, BMSC bone marrow-derived stromal cell, IGF-1 insulin-like
growth factor-1, PDC periosteum-derived cell
Fig. 5 rhBMP-2/7 treatment (300 ng/ml) upregulates osteogenic gene
expression and suppresses adipogenic gene expression in diabetic
PDCs, but not in diabetic BMSCs, in high glucose (25 mM) osteogenic
cultures. Relative Col1, OCN, GLUT1, and PPARγ expressions (n = 3) in a
diabetic PDCs and b diabetic BMSCs in high glucose osteogenic
cultures with rhBMP2/7 treatment are reported relative to that of the
respective cultures without BMP-2/7 treatment (set to 1). *p < 0.05
(Student’s t test) for pairwise comparisons between cultures with and
without growth factor rescue for a given cell type; error bars, standard
deviation of the mean. BMP-2/7 bone morphogenetic protein-2/7
heterodimer, BMSC bone marrow-derived stromal cell, PDC
periosteum-derived cell, Col 1 type 1 collagen, GLUT1 glucose
transporter 1, PPARγ peroxisome proliferator-activated receptor gamma,
OCN osteocalcin
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mineralized matrices, upon culture induction com-
pared with their nondiabetic counterparts, even when
cultured in normal glucose media. Diabetic PDCs
were found to proliferate slightly better than diabetic
BMSCs, but underwent even poorer osteogenic differ-
entiation than diabetic BMSCs in normal glucose
osteogenic media. Although it was previously shown
that restoring normal insulin levels could improve
bone quality in T1DM patients [42], early interven-
tion is needed to prevent detrimental “metabolic
memory” caused by hyperglycemia [43]. Our observa-
tion that skeletal progenitors isolated from T1DM
rats with poorly controlled blood glucose exhibit
significant cellular impairments in normal glucose
cultures supports that restoring normal blood glucose
alone may not be sufficient in rescuing skeletal
comorbidities of T1DM. Additionally, we found that
the impaired osteogenesis of diabetic BMSCs was ac-
companied with more potent adipogenic differentiation
upon culture induction, consistent with literature reports
on the increased bone marrow adiposity in T1DM rodents
[44]. There was no difference, however, in the adipogene-
sis of diabetic PDCs compared with nondiabetic PDCs.
This observation suggests that mechanisms underlying
the observed impairment of osteogenic differentiation
of diabetic BMSCs and PDCs may differ.
Most earlier in-vitro studies on the cellular effects of high
glucose were carried out with nondiabetic cells giving
sometimes discrepant results [37, 39, 45–47], with some
showing that high glucose compromises bone marrow cell
growth and osteogenic differentiation or quality of mineral
deposition [45–47]. Here we found that the proliferative
potential of diabetic skeletal progenitors further diminished
(marginally in diabetic PDCs, significantly in diabetic
BMSCs) in high glucose culture. Interestingly, whereas high
glucose also further suppressed the osteogenic differenti-
ation of diabetic BMSCs, it appeared to have some positive
effect on the osteogenesis of diabetic PDCs (although still
significantly impaired compared with the osteogenesis of
nondiabetic PDCs in normal glucose culture).
We then evaluated whether and how diabetic BMSCs
and PDCs may differentially respond to the osteogenesis
rescue in normal glucose and high glucose cultures by
osteogenic factor BMP-2/7 heterodimer and/or IGF-1.
We showed that both diabetic BMSCs and PDCs
responded robustly to the rhBMP-2/7 rescue in a dose-
dependent manner in normal glucose osteogenic culture,
restoring their osteogenesis to the level comparable with
(45 ng/ml treatment for diabetic BMSCs) or far beyond
those of normal progenitors. By contrast, these diabetic
progenitors responded only marginally to rhIGF-1 in
normal glucose osteogenic culture. IGF-1 is an anabolic
factor for skeletal growth known to be downregulated in
poorly controlled T1DM [29–31]. It was previously
shown to promote matrix mineralization by osteoblasts
under high glucose conditions [48] and aid healing in
calvarial defects in streptozocin-induced diabetic rats
[49]. Here, we did not observe sufficient rescue of the
impaired osteogenesis of diabetic BMSCs and PDCs by
rhIGF-1 treatment alone even at doses consistent with
the aforementioned literature reports. Although we
showed that dual treatment of rhIGF-1 and rhBMP-2/7
resulted in statistically significant further enhancement
in osteogenesis compared with rhBMP-2/7 treatment
alone, no apparent synergistic benefits beyond the sum
of enhancements of the respective single factor treat-
ments was observed. In all cases, the diabetic PDCs
responded more readily to these growth factor treat-
ments than diabetic BMSCs in normal glucose culture.
In high glucose culture, only the diabetic PDCs
responded to the rescue by rhBMP-2/7 or rhBMP-2/7 +
rhIGF-1 in a dose-dependent manner while the significantly
impaired osteogenesis of diabetic BMSCs remained com-
pletely suppressed and was unresponsive to the growth
factor treatments. qPCR confirmed that diabetic PDCs
responded to the rhBMP-2/7 rescue in high glucose osteo-
genic media by upregulations of early stage (COL1) and late
stage (OCN) osteogenic markers and the glucose trans-
porter GLUT1 known to positively correlate to osteoblastic
differentiation [41], as well as the downregulation of
adipogenic marker PPARγ. By contrast, diabetic BMSCs
only exhibited a small increase in COL1 expression
but no significant changes in OCN or GLUT1 expres-
sion after 2 weeks of rhBMP-2/7 treatment in high
glucose osteogenic media. The adipogenic marker
PPARγ expression in diabetic BMSCs even saw an in-
crease upon rhBMP-2/7 treatment. These data further
support the likelihood of differing mechanisms by
which the two skeletal progenitor cells are impaired
in a hyperglycemia environment, and thus the need to
tailor the therapeutic strategies for T1DM bone healing
based on specific cellular niches.
The effectiveness of rhBMP-2/7 in rescuing osteogen-
esis of diabetic PDCs in both normal and high glucose
cultures demonstrated in this study supports the concept
of local delivery of the osteogenic factor to the periosteal
surface (e.g., via a resorbable mesh) to expedite retarded
diabetic fracture healing, a significant clinical challenge
among T1DM patients. It is worth investigating whether
expedited diabetic fracture healing may be accomplished
using clinically safe doses of the osteogenic factor with
and without tight blood glucose control. Meanwhile, this
study also underscores the unique challenge in rescuing
the highly suppressed osteogenesis of diabetic BMSCs in
the presence of persisted hyperglycemia. It is likely that
impaired secretion of signaling molecules other than
BMP-2, BMP-7, and IGF-1 in the bone marrow niche in
T1DM will need to be rescued. For instance, increased
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secretion of inflammatory cytokines within T1DM bone
marrow microenvironment [14, 29] and impaired angio-
genesis [50, 51], a process known to be tightly coupled
with osteogenesis during bone regeneration [52], has been
reported in T1DM. It would be of interest to examine
whether exogenous stromal derived factor SDF-1, shown
to promote anti-inflammatory monocyte recruitment and
stimulate vascular remodeling [53], and/or angiogenic
factors (e.g., VEGF [54], sphingocine-1-phosphate [55]),
could help more effectively rescue the osteogenesis of
diabetic BMSCs in vitro and in vivo in the presence of
hyperglycemia. Such an investigation will be particularly
relevant for developing effective therapeutic strategies
toward the regenerative repair of traumatic diabetic bony
injuries (e.g., segmental bone loss) that disrupt the bone
marrow niche, a condition less prevalent than fractures
but far more clinically challenging.
Conclusions
This study demonstrates that BMSCs and PDCs isolated
from T1DM BBDP rats exhibited impaired proliferation
and osteogenesis in vitro, and that these impairments were
exacerbated in high glucose cultures. We showed that
impaired osteogenesis of diabetic PDCs could be fully
rescued by rhBMP-2/7 (45 or 300 ng/ml) with/without
rhIGF-1 (15 or 100 ng/ml) in both normal and high
glucose cultures in a dose-dependent manner. Diabetic
BMSCs, however, only responded to the 300 ng/ml
rhBMP-2/7 rescue with/without 100 ng rhIGF-1 in
normal but not high glucose osteogenic cultures. IGF-1
alone was insufficient in rescuing the osteogenesis of
either diabetic progenitor in the doses examined.
Our findings support the benefit of restoring normal
blood glucose while delivering exogenous protein therapeu-
tics compared with either approach alone in rescuing im-
paired T1DM bone healing. Furthermore, the findings that
diabetic PDCs are more responsive than diabetic BMSCs to
BMP-2/7 rescue in a hyperglycemia environment points to
an exciting opportunity to rescue diabetic fracture healing,
a prevalent clinical problem, via local delivery of the thera-
peutics to periosteal surfaces of the fracture. Finally, our
study also underscores the unique challenge in rescuing the
highly suppressed osteogenesis of diabetic BMSCs in the
presence of hyperglycemia. Alternative/additional biochem-
ical therapeutics tailored to the diabetic bone marrow niche
will need to be identified to more effectively facilitate the
regenerative repair of traumatic diabetic bony injuries that
disrupt the bone marrow niche.
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